User menu

The impact of reimbursement criteria on the appropriateness of 'statin' prescribing.

Bibliographic reference Autier, Philippe ; Creplet, Jean ; Vansant, Greet ; Brohet, Christian ; Paquot, Nicolas ; et. al. The impact of reimbursement criteria on the appropriateness of 'statin' prescribing.. In: European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, Vol. 10, no. 6, p. 456-62 (2003)
Permanent URL
  1. LaRosa John C., He Jiang, Vupputuri Suma, Effect of Statins on Risk of Coronary Disease : A Meta-analysis of Randomized Controlled Trials, 10.1001/jama.282.24.2340
  2. Hebert Patricia R., Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total Mortality : An Overview of Randomized Trials, 10.1001/jama.1997.03550040069040
  3. Bucher Heiner C., Effect of HMGcoA Reductase Inhibitors on Stroke : A Meta-Analysis of Randomized, Controlled Trials, 10.7326/0003-4819-128-2-199801150-00002
  4. Wood David A, Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries, 10.1016/s0140-6736(00)04235-5
  5. Pearson Thomas A, Peters Theodore D, The Treatment Gap in Coronary Artery Disease and Heart Failure: Community Standards and the Post-Discharge Patient, 10.1016/s0002-9149(97)00820-5
  6. The Scandinavian Simvastatin Survival Study Group, Lancet, 344, 1383 (1994)
  7. Shepherd James, Cobbe Stuart M., Ford Ian, Isles Christopher G., Lorimer A. Ross, Macfarlane Peter W., McKillop James H., Packard Christopher J., Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia, 10.1056/nejm199511163332001
  8. Sacks Frank M., Pfeffer Marc A., Moye Lemuel A., Rouleau Jean L., Rutherford John D., Cole Thomas G., Brown Lisa, Warnica J. Wayne, Arnold J. Malcolm O., Wun Chuan-Chuan, Davis Barry R., Braunwald Eugene, The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels, 10.1056/nejm199610033351401
  9. Montagne Olivier, Vedel Isabelle, Durand-Zaleski Isabelle, Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations, 10.1016/s0149-2918(00)86748-x
  10. Gould A. L., Rossouw J. E., Santanello N. C., Heyse J. F., Furberg C. D., Cholesterol Reduction Yields Clinical Benefit : Impact of Statin Trials, 10.1161/01.cir.97.10.946
  11. Recommandations pour le diagnostic et le traitement des hyperlipidémies (in French and in Dutch) (1999)
  12. Wood David, De Backer Guy, Faergeman Ole, Graham Ian, Mancia Giuseppe, Pyörälä Kalevi, Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (Summary only) 1998;16(10).2, 10.1016/s0021-9150(98)90209-x
  13. Grundy Scott M., Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), 10.1001/jama.1993.03500230097036
  14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 10.1001/jama.285.19.2486
  15. Haffner S. M., Management of Dyslipidemia in Adults With Diabetes, 10.2337/diacare.21.1.160
  16. Pyorala K., Pedersen T. R., Kjekshus J., Faergeman O., Olsson A. G., Thorgeirsson G., , Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), 10.2337/diacare.20.4.614
  17. Prosser Lisa A., Stinnett Aaron A., Goldman Paula A., Williams Lawrence W., Hunink Maria G.M., Goldman Lee, Weinstein Milton C., Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics, 10.7326/0003-4819-132-10-200005160-00002
  18. Muls Erik, Autier Philippe, Malbecq William, Vansant Greet, Coronary Heart Disease Risk Factors and LDL Cholesterol-Lowering Efficacy of Fibrates and Simvastatin : , 10.2165/00044011-199714020-00003
  19. Bruckert E., De Gennes J. L., Malbecq W., Baigts F., Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia, 10.1002/clc.4960181107
  20. ANNEMANS L, DE BACKER G, DE BACQUER D, DE HENAUW S, KORNITZER M, Preventie van coronaire aandoeningen in België: kostprijs van statines, 10.2143/tvg.57.13.5001092